Drugs / GRT-R910
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05148962 | Sep 2021 → May 2023 | COVID-19 | Gritstone bio, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRT-R910 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05148962 ↗ |
| Modality | Messenger RNA (mRNA) | “GRT-R910 is an investigational self-amplifying mRNA (samRNA)-based SARS-CoV-2 vaccine delivering full-length Spike and selected conserved non-Spike T cell epitopes.” PMID 37280238 ↗ Jun 2023 |
| Route | Intramuscular | “Injection administered intramuscularly” NCT05148962 ↗ |